Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of "Reduce" by Analysts
Analysts have given Pacific Biosciences of California, Inc. (NASDAQ:PACB) an average "Reduce" recommendation, with an average 12-month price target of $1.83, significantly higher than its opening price of $1.23. The company recently missed quarterly earnings expectations, reporting a loss of $0.14 per share against an estimated $0.13, and revenue of $39.01 million compared to $42.90 million expected. Despite the stock trading near its 12-month low, several institutional investors have increased their holdings.
Pacific Biosciences CEO Mark van Oene sells $30,409 in stock
Pacific Biosciences CEO Mark van Oene sold 26,911 shares of the company's common stock for a total of $30,409. This transaction was to cover tax withholding obligations associated with restricted stock units. Following the sale, Van Oene directly holds over 2.7 million shares, while the company's stock trades near its 52-week low.
Pacific Biosciences CEO Mark van Oene sells $30,409 in stock
Pacific Biosciences CEO Mark van Oene sold 26,911 shares of company stock for $30,409 on August 17, 2026. This transaction was primarily to cover tax withholding obligations associated with the vesting of restricted stock units. The sale occurred as PACB stock trades near its 52-week low, and the company recently reported a revenue miss and adjusted its full-year outlook.
Insider Selling: Pacific Biosciences of California (NASDAQ:PACB) Insider Sells 26,911 Shares of Stock
Pacific Biosciences of California (NASDAQ:PACB) insider Oene Mark Van sold 26,911 shares of the company's stock for approximately $30,409. The sale was primarily to cover tax withholding obligations related to vested equity awards, reducing his holdings by 0.98%. This transaction occurred as PACB shares traded near their 12-month low after reporting quarterly results that missed analyst expectations, leading to a "Reduce" consensus rating from analysts.
PacBio (NASDAQ: PACB) CEO share sale covers RSU tax withholding
PacBio (NASDAQ: PACB) CEO Mark Van Oene sold 26,911 shares of common stock on August 17, 2026, at a weighted average price between $1.13 and $1.15 per share. This sale was automatically conducted to cover tax withholding obligations associated with the vesting of restricted stock units, rather than being a discretionary market sale. Following the transaction, Van Oene directly holds 2,705,853 shares of PACB common stock.
PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity
Pacific Biosciences of California (PacBio) has lowered its revenue outlook due to a slower-than-expected customer transition to its lower-priced SPRQ-Nx chemistry and weakening demand for Vega systems from academic and government sectors. The company is implementing a restructuring to cut costs, aiming for $15 million to $20 million in annual compensation savings and an additional $30 million to $40 million reduction in spending by 2027. PacBio is targeting cash-flow positivity by 2028, contingent on launching a new ultra-high-throughput platform, improving compute economics, and achieving gross margins near 50%.
PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity
PacBio has revised its revenue outlook downward due to a slower-than-anticipated customer transition to its lower-priced SPRQ-Nx chemistry and weakened demand for Vega systems from academic and government sectors. The company is implementing cost-reduction measures, including a workforce reduction, targeting significant annual savings and a further spending reduction in 2027. PacBio aims for cash-flow positivity by 2028, contingent on the launch of a new ultra-high-throughput platform, improved compute economics, and successful customer conversion to SPRQ-Nx.
ARK reports 9.59% stake in Pacific Biosciences (PACB)
ARK Investment Management LLC and Catherine D. Wood have reported a beneficial ownership of 9.59% in Pacific Biosciences of California, Inc. (PACB), amounting to 29,781,416 shares. This disclosure, made via a SCHEDULE 13G/A filing, details their sole and shared voting and dispositive powers over these shares. The filing indicates a neutral sentiment and moderate impact on the stock.
PACIFIC BIOSCIENCES (PACB) CEO granted 1.97M options and 489K RSUs
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) CEO Mark Van Oene was granted 1.97 million stock options and 489,130 Restricted Stock Units (RSUs) on August 10, 2026. The stock options have an exercise price of $1.15 per share and vest over 36 monthly installments, while the RSUs vest in equal annual installments over three years. Following these grants, Van Oene directly holds 2,732,764 common shares of PACB.
Earnings Release: Here's Why Analysts Cut Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Price Target To US$2.29
Analysts have cut their price target for Pacific Biosciences of California (NASDAQ:PACB) to US$2.29 after the company reported a moderately negative quarterly result, with revenue falling short of estimates and statutory losses meeting expectations. The lowered price target reflects concerns about increased forecasted losses and slower revenue growth compared to the wider industry. Analysts now expect per-share losses to increase to US$0.44 in 2026, while revenue growth is predicted to slow significantly.
Pacific Biosciences of California, Inc. $PACB Shares Sold by Renaissance Technologies LLC
Renaissance Technologies LLC significantly reduced its stake in Pacific Biosciences of California (NASDAQ:PACB) by 35.4% in the first quarter, selling 1,361,500 shares. This comes as analyst sentiment for PACB is generally bearish, with an average "Reduce" rating and an average price target of $1.83. The company also reported a quarterly loss and revenue that missed analyst estimates.
Earnings Release: Here's Why Analysts Cut Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Price Target To US$2.29
Analysts have cut their price target for Pacific Biosciences of California (NASDAQ:PACB) to US$2.29 after the company reported quarterly results showing a 15% drop in investment. Revenues fell short of estimates, and while statutory losses were in line, analysts now expect increased losses for 2026 and slower revenue growth compared to the wider industry. The consensus price target has fallen, reflecting concerns about the company's future valuation and performance.
Earnings Release: Here's Why Analysts Cut Their Pacific Biosciences of California, Inc. (NASDAQ:PACB) Price Target To US$2.29
Analysts have lowered their price target for Pacific Biosciences of California (NASDAQ:PACB) to US$2.29 after the company's recent earnings report, which saw revenue fall short of estimates and increased projected losses per share for 2026. The revised forecasts indicate a slowdown in revenue growth compared to historical performance and expectations for the broader industry, prompting a more negative outlook from analysts.
Pacific Biosciences of California (NASDAQ:PACB) Cut to "Sell" at Wall Street Zen
Wall Street Zen has downgraded Pacific Biosciences of California (NASDAQ:PACB) from a "hold" to a "sell" rating. The company recently missed its quarterly earnings and revenue estimates, reporting a loss of $0.14 per share and $39.01 million in revenue. Analysts currently hold a "Reduce" consensus rating for PACB, with a target price of $1.83, and major institutional investors have adjusted their holdings in the company.
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 2026: Revenue $39.01M, EPS ($0.14) — 10-Q Summary
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) reported its current quarter 2026 results, showing largely flat revenue year-over-year at $39.01M and a net loss that widened to ($44.74M), though diluted EPS remained ($0.14). The company is focusing on shifting towards clinical and commercial accounts, increasing Revio adoption, and implementing operational efficiencies expected to reduce operating expenses by $30–$40M annually by the end of 2027. Key milestones include the SPRQ‑Nx launch, the sale of short‑read technology assets, and a licensing agreement with PGI.
Pacific Biosciences of California, Inc. Stock 12‑Month Price Target Cut to $2.29, Implies 76% Upside
The average 12-month price target for Pacific Biosciences of California, Inc. (PACB) stock has been lowered from $2.46 to $2.29 by 6 analysts, suggesting a potential upside of approximately 76% from its August 5th closing price. Despite the target cut, the consensus rating from 7 covering analysts remains a "Buy," with 4 Buys, 2 Holds, and 1 Sell recommendation.
Pacific Biosciences of California Q2 Earnings Call Highlights
Pacific Biosciences of California (NASDAQ: PACB) reported Q2 2026 revenue of $39 million, remaining flat year-over-year, alongside a leadership change and a reduced full-year revenue forecast. The company is facing challenges with the slower-than-expected rollout of its new SMRT Next sequencing chemistry and funding constraints in academic and government sectors. Despite these headwinds, PacBio is focusing on scaling its clinical-market approach and expects consumables growth to accelerate later in 2026 as customers adopt the new chemistry.
PacBio Announces Second Quarter 2026 Financial Results
PacBio reported its second-quarter 2026 financial results, with total revenue of $39.0 million, driven by growth in consumables and new Revio and Vega placements. The company also announced the global commercial rollout of its SPRQ-Nx chemistry, offering whole genome sequencing at a list price of $345 USD. Despite a GAAP net loss of $44.7 million, PacBio projects full-year 2026 revenue to be between $155 million and $165 million.
TD Cowen Maintains Pacific Biosciences of California(PACB.US) With Buy Rating, Maintains Target Price $3
TD Cowen has reiterated its Buy rating on Pacific Biosciences of California (PACB.US) and maintained its target price at $3. This indicates a continued positive outlook from the firm regarding the company's stock performance.
PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut
PacBio reported an adjusted loss per share of 14 cents for Q2 2026, meeting estimates, but revenues of $39 million missed expectations and were down 2% year over year. The company reduced its 2026 revenue guidance to $155-$165 million due to weaker instrument sales, funding constraints in the Americas and Asia-Pacific, and slower-than-expected adoption of new chemistry. Despite challenges, PacBio highlighted growth in consumables revenue, strong clinical demand, and increased revenues in EMEA.
Pacific Biosciences of California Q2 Earnings Call Highlights
Pacific Biosciences of California (PACB) reported Q2 2026 revenue of $39 million, largely flat year-over-year, and announced a leadership change with Mark Van Oene succeeding Christian Henry as CEO. The company lowered its full-year revenue outlook due to slower rollout of new sequencing chemistry and funding constraints in academic markets. Despite these challenges, PacBio saw growth in consumables revenue and highlighted the global rollout of its SMRT Next chemistry and the increasing adoption of long-read sequencing in clinical diagnostics.
ETFs Investing in Pacific Biosciences of California, Inc. Stocks
This article lists various ETFs that include Pacific Biosciences of California, Inc. (PACB) stocks in their holdings. It provides a detailed table for each ETF, including market value, weight, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The ETFs cover different investment strategies, such as thematic, small-cap, and healthcare-focused funds.
PacBio Appoints Mark Van Oene as President and Chief Executive Officer
PacBio has announced the appointment of Mark Van Oene as its new President and Chief Executive Officer, effective August 5, 2026. He succeeds Christian Henry, who led the company for six years and will remain on the Board and serve as a business advisor for a smooth transition. Van Oene, previously COO, has played a key role in advancing PacBio's operational execution, commercial strategy, product development, and AI-related initiatives, particularly focusing on expanding into clinical markets and AI-enabled product solutions.
Pacific Biosciences: It's Only Getting Worse (NASDAQ:PACB)
Pacific Biosciences reported disappointing Q2 revenues of $39.01 million, missing estimates and lowering its 2026 revenue guidance below consensus. The company continues to face sizable operating and net losses, with cash reserves dwindling and significant debt outstanding. Despite trading at a steep discount to peers at 2.4x expected 2026 revenues, the outlook remains bleak due to weak financials and growth prospects.
PacBio Q2 2026 slides: SPRQ-Nx launch amid revenue miss, cut guidance
Pacific Biosciences (NASDAQ:PACB) reported a mixed Q2 2026, launching its SPRQ-Nx sequencing chemistry but missing revenue expectations and lowering full-year guidance. The company's stock declined following the announcement, as it also delayed its cash flow breakeven target to 2028. Despite clinical validation of its HiFi sequencing technology, PacBio faces challenges in translating product innovation into sustainable revenue growth amid funding uncertainties and the need for broader SPRQ-Nx adoption.
PacBio Announces Second Quarter 2026 Financial Results
PacBio announced its second-quarter 2026 financial results, reporting total revenue of $39.0 million, driven by growth in consumables and placements of its Revio and Vega systems. The company also highlighted the global commercial rollout of its SPRQ-Nx chemistry, significant milestones in population-scale genomics, and publications demonstrating the clinical effectiveness of its HiFi long-read sequencing. Despite a GAAP net loss of $44.7 million, PacBio provided a full-year 2026 revenue outlook ranging from $155 million to $165 million.
PacBio Announces Second Quarter 2026 Financial Results
PacBio reported total revenue of $39.0 million for Q2 2026, driven by growth in consumables and new Revio and Vega system placements. The company commenced the global commercial rollout of its SPRQ-Nx chemistry and published significant research demonstrating the clinical effectiveness of HiFi long-read sequencing. Despite a GAAP net loss of $44.7 million, PacBio provided a full-year 2026 revenue outlook of $155 million to $165 million.
PacBio Vega adds two- and four-hour runs for short-insert DNA
PacBio announced updates to its Vega sequencing system, including the SPRQ-Nx chemistry and a software update. These enhancements increase HiFi output from 60 Gb to 90 Gb per run, lower the U.S. list price, and introduce two- and four-hour sequencing runs. The changes aim to reduce cost per gigabase by 40%, lower DNA input requirements, and add compliance controls and improved methylation callers, making the system more versatile for various short-insert applications.
Pacific Biosciences of California, Inc. Q2 2026 Earnings Call Summary
Pacific Biosciences of California, Inc. (PACB) released its Q2 2026 earnings summary, highlighting strategic shifts including a new CEO, targeted reorganization for clinical market growth, and the global launch of SPRQ-Nx chemistry which reduces genome sequencing costs. Despite a 67% increase in clinical consumable shipments and a rebound in Revio instrument placements, the company lowered its 2026 revenue guidance to $155M-$165M and extended its cash flow breakeven timeline to 2028 due to inventory burn-down, China recovery, and funding constraints. Management anticipates significant volume driving from SPRQ-Nx in the second half of 2026 and plans further restructuring for cost savings.
PACB5949325 Bond Profile — Key Metrics
This article provides a detailed profile of the PACB5949325 bond issued by Pacific Biosciences of California, Inc. Key metrics include a 1.5% coupon rate, an issue date of November 21, 2024, and a maturity date of August 15, 2029. The bond has an outstanding amount of $200.00 million USD.
PACB5949325 Bond Risk Profile
This page provides a risk profile for the PACB5949325 bond issued by Pacific Biosciences of California, Inc. It details the bond's coupon, redemption information, and a credit risk assessment section, including security level and issuer rating. The platform also offers access to analyst ratings for bonds.
Pacific Biosciences of California Inc (PACB) Financial Health: Profitability & Balance Sheet Analysis
This article provides a financial health analysis of Pacific Biosciences of California Inc (PACB), noting its current financial score of 5.83, which ranks it low within the Healthcare Equipment & Supplies industry. Despite its weak financial status and low operating efficiency, the company reported a significant year-over-year increase in net profit by 98.06%, alongside a 0.07% increase in quarterly revenue to $37.18 million. The report also highlights that key financial data for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not yet been disclosed by the company.
Pacific Biosciences of California Inc (PACB) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Pacific Biosciences of California Inc (PACB), detailing its volatility, financial risk, and investment risk. The company's risk assessment score is 3.44, ranking it 120 out of 199 in the Healthcare Equipment & Supplies industry. Key metrics such as beta value, maximum drawdown, volatility, and Sharpe ratios are presented to quantify PACB's risk profile.
PACB5608751 Bond Profile — Key Metrics
This article provides key metrics for the PACB5608751 bond issued by Pacific Biosciences of California, Inc. The bond has a 1.5% coupon rate and matures on February 15, 2028. It also details company information, including its focus on advanced sequencing solutions and its geographical segments.
PACB5630687 Bond Profile — Key Metrics
This article provides a detailed profile of the PACB5630687 bond issued by Pacific Biosciences of California, Inc. Key metrics include its 1.375% coupon, maturity date of December 15, 2030, and an outstanding amount of $441 million. The company, founded in 2000, specializes in advanced sequencing solutions for genetic analysis.
Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why
Pacific Biosciences of California (PACB) closed up 2.21% in its latest trading session, outperforming the S&P 500. The company is set to release its earnings on August 5, 2026, with an expected year-over-year decline in EPS but a rise in revenue. Analysts' estimate revisions and the company's Zacks Rank of #3 (Hold) suggest ongoing investor interest in its near-term performance.
PacBio to Participate in the Canaccord Genuity 46th Annual Growth Conference
PacBio (NASDAQ: PACB) announced its participation in the upcoming Canaccord Genuity 46th Annual Growth Conference. Christian Henry, President and Chief Executive Officer, is scheduled to present on Wednesday, August 14, 2024, at 9:00 AM ET. A live audio webcast will be available for those wishing to attend virtually.
PacBio Management Chat Set for Aug. 11 With Live Webcast
PacBio (NASDAQ: PACB) announced that its management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026, at 9:00 AM ET in Boston, Massachusetts. A live webcast and replay will be available on the company’s investor website. The news release provides details about accessing the webcast and replay, as well as PacBio's company profile and product applications.
Pacific Biosciences of California Inc (PACB) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Pacific Biosciences of California Inc (PACB), listing major individual and institutional holders. It provides a breakdown of shareholder types, institutional shareholding over time from Q4 2023 to Q1 2026, and a list of related ETFs that hold PACB shares. Key holders include ARK Investment Management LLC and SoftBank Group Corp.
Pacific Biosciences of California Inc (PACB) Institutional Confidence
This article analyzes the institutional confidence score for Pacific Biosciences of California Inc (PACB), which stands at 5.00, placing it 107th in the Healthcare Equipment & Supplies industry. Institutional shareholding proportion increased by 10.93% quarter-over-quarter to 62.12%. Catherine Wood is the largest institutional shareholder with 37.12 million shares, representing 11.68% of shares outstanding.
Pacific Biosciences of California, Inc. Revenue Breakdown – NASDAQ:PACB
Pacific Biosciences of California, Inc. (NASDAQ: PACB) generated a total revenue of $160.00 million USD last year. The "Consumable" segment was the top-performing segment, contributing $81.94 million USD, an increase from $70.37 million USD in the previous year. Geographically, the United States was the largest contributor to revenue, bringing in $69.70 million USD last year.
Pacific Biosciences of California Inc
This article provides a detailed revenue breakdown for Pacific Biosciences of California Inc (PACB), categorized by business segments and geographical regions. As of April 6, the company's revenue is primarily driven by consumable sales (51.21%), followed by instrument sales (33.64%) and service/other revenue (15.15%). Geographically, North America accounts for the largest share of revenue (45.50%).
PACB Cash Flow Statement
This article presents the quarterly and annual cash flow statements for Pacific Biosciences of California Inc (PACB), detailing operating, investing, and financing cash flows from FY2012Q1 to FY2026Q1. It provides a comprehensive breakdown of various cash flow components, including net income, operating gains/losses, deferred tax, other non-cash items, and changes in working capital. The page also includes frequently asked questions explaining cash flow definitions and recent figures for PACB.
PACB|Pacific Biosciences of California Inc|Price:1.360|Chg%:-0.040
This article provides an overview of Pacific Biosciences of California Inc (PACB), a life science technology company specializing in advanced sequencing solutions. It details the company's products, technologies like HiFi long-read sequencing, and applications in various scientific fields. The article also lists company information, executive details, and key shareholder insights, including institutional holdings and revenue sources.
PACB|Pacific Biosciences of California Inc|Price:1.360|
This report provides a comprehensive stock analysis of Pacific Biosciences of California Inc (PACB) by TradingKey. It highlights the company's relatively weak fundamentals but significant growth potential, with its valuation considered fairly valued within the Healthcare Equipment & Supplies industry. The analysis also notes high institutional ownership, recent "Buy" ratings from analysts with a target price of $2.46, and the stock's sideways trading pattern in the short term.
Pacific Biosciences of California Inc (PACB) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Pacific Biosciences of California Inc (PACB) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent dividend payouts. The page also presents current stock performance data, including its market cap and recent price change.
PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026
PacBio (NASDAQ: PACB) announced it will report its second-quarter 2026 financial results on Wednesday, August 5, 2026, at 4:30 p.m. Eastern Time. The company will host a conference call and webcast, accessible via its investor relations website, to discuss these results. PacBio is a life science technology company specializing in advanced sequencing solutions for various research applications.
PacBio’s next earnings update will stream live Aug. 5
PacBio (NASDAQ: PACB) announced that it will host a quarterly conference call on Wednesday, August 5, 2026, at 4:30 p.m. Eastern Time, to discuss its second quarter 2026 financial results. Investors can access the live webcast or replay via PacBio's investor relations website or by using provided dial-in numbers. The announcement notes that similar previous earnings date notices have resulted in mixed single-day stock reactions.
PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026
PacBio (NASDAQ: PACB) announced it will hold a quarterly conference call to discuss its second-quarter 2026 financial results on Wednesday, August 5, 2026, at 4:30 p.m. Eastern Time. The call will be webcast and accessible via the company's investor relations website. This call will cover the company's performance as a premier life science technology company specializing in advanced sequencing solutions.
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know
Pacific Biosciences of California (PACB) shares dropped 4.49% recently, underperforming the broader market despite a 19.08% gain over the past month. The company is expected to report an EPS of -$0.14 and revenue of $42.1 million in its upcoming earnings, with analysts maintaining a "Buy" rating (Zacks Rank #2). Investors are advised to monitor analyst estimate revisions as they often signal future stock movements.
